North America Biologics CDMO Market Size by Applications, by Type, by End-User, by Deployment & by Technology 2032
North America Biologics CDMO Market was valued at USD 1.5 Billion in 2022 and is projected to reach USD 3.0 Billion by 2030, growing at a CAGR of 9.6% from 2024 to 2030.
The North America Biologics CDMO market is experiencing rapid expansion, driven by the increasing demand for biologic drugs, advances in cell and gene therapies, and outsourcing trends among pharmaceutical companies. As of 2024, North America accounts for approximately 36% of the North America biologics CDMO sector, with projections indicating market growth from USD 7.9 billion in 2024 to USD 23.6 billion by 2034.
Biologics CDMOs (Contract Development and Manufacturing Organizations) play a crucial role in the pharmaceutical supply chain by offering end-to-end services, from drug development to large-scale production. Companies such as Lonza, Catalent, and Samsung Biologics have established advanced facilities to meet the rising demand for monoclonal antibodies, recombinant proteins, and viral vector manufacturing.
Industry Applications and Trends
- Oncology and Autoimmune Therapies: With over 2 million cancer cases projected in the U.S. by 2025, biologics such as monoclonal antibodies are increasingly used in targeted cancer therapies.
- Gene and Cell Therapy Expansion: The demand for viral vector production has surged as companies develop therapies for rare diseases and regenerative medicine.
- Microbial and Mammalian Cell Culture: The mammalian cell segment dominates the market due to its efficiency in producing complex biologics, while microbial systems provide cost-effective solutions for certain biologic drugs.
- Technological Advancements: AI-driven bioprocessing, continuous manufacturing, and single-use bioreactors enhance efficiency and scalability.
- Regulatory Influence: The U.S. FDA’s clear regulatory framework fosters innovation and investment, accelerating drug approvals.
- Environmental Sustainability: CDMOs are integrating green technologies to reduce carbon footprints, as the pharma sector contributes significantly to greenhouse gas emissions.
Challenges and Industry Requirements
- High Operational Costs: North America faces rising production costs, making cost-effective solutions a necessity.
- Workforce Shortages: A skilled labor gap in biopharmaceutical manufacturing hinders rapid scaling.
- Supply Chain Disruptions: Geopolitical factors and raw material shortages impact production timelines.
- Competitive Pressure: Asia-Pacific CDMOs offer lower-cost manufacturing, challenging North American dominance.
Despite these challenges, North America remains the leader in high-quality biologics manufacturing due to its technological expertise, robust infrastructure, and strong regulatory framework. The continued investment in advanced biomanufacturing and sustainability practices will further drive growth in the North America Biologics CDMO Market.
Get an In-Depth Research Analysis of the North America Biologics CDMO Market Size And Forecast [2025-2032]
Who are the largest North America manufacturers in the Biologics CDMO industry?
- Lonza Group AG
- Samsung Biologics
- AbbVie
- WuXi Biologics
- Toyobo
- AGC
- Thermo Fisher Scientific
- ICON Plc
- Boehringer Ingelheim
- Fujifilm Diosynth Biotechnologies
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the North America Biologics CDMO Market Size And Forecast [2025-2032]
What are the factors driving the growth of the North America Biologics CDMO Market?
Growing demand for below applications around the world has had a direct impact on the growth of the North America Biologics CDMO Market
- Cell Therapy
- Drug Development
- Others
What are the types of Biologics CDMO available in the Market?
Based on Types the Market is categorized into Below types that held the largest Biologics CDMO market share In 2023.
- Biological Agent
- Biosimilar Drug
Which regions are leading the North America Biologics CDMO Market?
- North America (United States, North America and Mexico)
- Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
- Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
- South America (Brazil, Argentina, Columbia, etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Biologics CDMO Market Research Analysis
Detailed TOC of North America Biologics CDMO Market Research Report, 2024-2032
1. Introduction of the North America Biologics CDMO Market
- Overview of the Market
- Scope of Report
- Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
- Data Mining
- Validation
- Primary Interviews
- List of Data Sources
4. North America Biologics CDMO Market Outlook
- Overview
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Porters Five Force Model
- Value Chain Analysis
5. North America Biologics CDMO Market, By Type
6. North America Biologics CDMO Market, By Application
7. North America Biologics CDMO Market, By Geography
- North America
- Europe
- Asia Pacific
- Rest of the World
8. North America Biologics CDMO Market Competitive Landscape
- Overview
- Company Market Ranking
- Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading North America Research and Consulting firm servicing over 5000+ North America clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768